Artiva shutters after two patient deaths in autoimmune cell therapy trials

· Health · United States

Artiva Biotherapeutics announced it is effectively shutting down and laying off almost all of its staff after two patients died in its clinical trials of autoimmune cell therapies. The company had been testing cancer-therapy strategies in autoimmune disease. The disclosure makes Artiva the third company recently to report fatal events in an autoimmune cell therapy trial, following Novartis and Bristol Myers Squibb. A patient who received Bristol Myers' zola-cel died 44 days after treatment, according to a separate report. The deaths are a setback for the broader effort to apply CAR-T and similar approaches beyond oncology, an area that had drawn intense industry interest as a new growth frontier.

Why it matters：Fatal events across multiple sponsors could slow the whole push to extend cell therapy into autoimmune disease, prompting tighter trial designs and a rethink of safety expectations for a field investors had treated as the next big market.

Key points

  • Artiva is cutting almost all staff as it winds down.
  • It is the third company recently to report a fatal autoimmune cell therapy event, after Novartis and Bristol Myers Squibb.
  • A Bristol Myers patient died 44 days after receiving zola-cel.

Sources (original reporting)

More stories from this day